• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Emerg Microbes Infect . Pre-optimized phage therapy on secondary Acinetobacter baumannii infection in four critical COVID-19 patients

tetano

Editor, Senior Moderator
Emerg Microbes Infect


. 2021 Mar 11;1-31.
doi: 10.1080/22221751.2021.1902754. Online ahead of print.
Pre-optimized phage therapy on secondary Acinetobacter baumannii infection in four critical COVID-19 patients


Nannan Wu[SUP] 1 [/SUP], Jia Dai[SUP] 1 [/SUP], Mingquan Guo[SUP] 1 2 [/SUP], Jianhui Li[SUP] 1 [/SUP], Xin Zhou[SUP] 1 [/SUP], Feng Li[SUP] 3 [/SUP], Yuan Gao[SUP] 4 [/SUP], Hongping Qu[SUP] 5 [/SUP], Hongzhou Lu[SUP] 6 [/SUP], Jing Jin[SUP] 7 [/SUP], Tao Li[SUP] 8 [/SUP], Lei Shi[SUP] 9 [/SUP], Qingguo Wu[SUP] 3 [/SUP], Ruoming Tan[SUP] 5 [/SUP], Mingli Zhu[SUP] 4 [/SUP], Lan Yang[SUP] 1 [/SUP], Yun Ling[SUP] 10 [/SUP], Shunpeng Xing[SUP] 4 [/SUP], Jianzhong Zhang[SUP] 11 [/SUP], Bangxin Yao[SUP] 11 [/SUP], Shuai Le[SUP] 1 12 [/SUP], Jingmin Gu[SUP] 1 13 [/SUP], Jinhong Qin[SUP] 1 14 [/SUP], Jie Li[SUP] 1 [/SUP], Mengjun Cheng[SUP] 1 [/SUP], Demeng Tan[SUP] 1 [/SUP], Linlin Li[SUP] 1 [/SUP], Yiyuan Zhang[SUP] 1 [/SUP], Zhaoqin Zhu[SUP] 2 [/SUP], Jinfeng Cai[SUP] 2 [/SUP], Zhigang Song[SUP] 15 [/SUP], Xiaokui Guo[SUP] 1 [/SUP], Li-Kuang Chen[SUP] 1 16 [/SUP], Tongyu Zhu[SUP] 1 17 [/SUP]



Affiliations

Abstract

Phage therapy is recognized as a promising alternative to antibiotics in treating pulmonary bacterial infections, however, its use has not been reported for treating secondary bacterial infections during virus pandemics such as coronavirus disease 2019 (COVID-19). We enrolled 4 patients hospitalized with critical COVID-19 and pulmonary carbapenem-resistant Acinetobacter baumannii (CRAB) infections to compassionate phage therapy (at 2 successive doses of 10[SUP]9[/SUP] plaque forming unit phages). All patients in our COVID-19-specific intensive care unit (ICU) with CRAB positive in bronchoalveolar lavage fluid or sputum samples were eligible for study inclusion if antibiotic treatment failed to eradicate their CRAB infections. While phage susceptibility testing revealed an identical profile of CRAB strains from these patients, treatment with a pre-optimized 2-phage cocktail was associated with reduced CRAB burdens. Our results suggest the potential of phages on rapid responses to secondary CRAB outbreak in COVID-19 patients.

Keywords: COVID-19; Carbapenem-resistant Acinetobacter baumannii, Nosocomial infections; Phage therapy.
 
Back
Top Bottom